Coya Therapeutics Halts Progression of Alzheimers in Small Study
Yesterday’s news from Coya Therapeutics (COYA) flew straight under the radar. Coya needs to maintain their standing in the scientific community as a company doing hard science research. An overly promotional PR would reduce their standing with the FDA down the road. But I’m here to translate.
COYA 301, also known as LD IL-2 or low-dose interleukin-2, was…
Keep reading with a 7-day free trial
Subscribe to Microcap Opportunities to keep reading this post and get 7 days of free access to the full post archives.